“Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s73. doi:10.25251/skin.6.supp.73.